- Home
- HOLO vs PMN Comparison
HOLO vs PMN Comparison
Compare HOLO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | PMN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | China | Canada |
| Employees | 64 | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 34.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HOLO | PMN |
|---|---|---|
| Price | $2.15 | $24.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | ★ 341.0K | 48.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.29 |
| 52 Week High | $12.75 | $27.40 |
Technical Indicators
Market Signals| Indicator | HOLO | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 73.44 |
| Support Level | $2.02 | $0.43 |
| Resistance Level | $2.30 | N/A |
| Average True Range (ATR) | 0.12 | 2.61 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 24.00 | 73.79 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.